- Previous Close
8.37 - Open
8.32 - Bid 8.41 x 100
- Ask 8.49 x 100
- Day's Range
8.14 - 8.51 - 52 Week Range
3.92 - 13.24 - Volume
283,802 - Avg. Volume
408,228 - Market Cap (intraday)
529.128M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.90 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.29
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
www.treace.comRecent News: TMCI
View MorePerformance Overview: TMCI
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMCI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMCI
View MoreValuation Measures
Market Cap
529.13M
Enterprise Value
523.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.51
Price/Book (mrq)
4.69
Enterprise Value/Revenue
2.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.63%
Return on Assets (ttm)
-14.83%
Return on Equity (ttm)
-44.45%
Revenue (ttm)
209.36M
Net Income Avi to Common (ttm)
-55.74M
Diluted EPS (ttm)
-0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
75.68M
Total Debt/Equity (mrq)
61.70%
Levered Free Cash Flow (ttm)
-30.01M